EdgeScore

BJDX · Nasdaq

Bluejay Diagnostics, Inc.: financial statements

Insufficient data · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2022: $249KNet income 2022: -$9.3M2022
RevenueNet income

Operating and free cash flow

Operating cash flow 2022: -$7.7MFree cash flow 2022: -$8.9M2022
Operating cash flowFree cash flow

Income statement

USD2022Last year
Revenue$249K
Gross profit$48.9K
Selling, general & admin$451K
Operating income-$9.3M
EBITDA-$9.2M
Interest expense$364
Net income-$9.3M

Cash flow

USD2022Last year
Operating cash flow-$7.7M
Capital expenditure$1.2M
Free cash flow-$8.9M
Depreciation & amortization$157K

Balance sheet

USD2022Last year
Cash$10.1M
Current assets$11.8M
Total assets$13.5M
Current liabilities$1.6M
Total liabilities$2.0M
Shareholders' equity$11.5M
Net debt-$10.1M

Ratios

2022Last year
Gross margin19.6%
Operating margin-3741.5%
Net margin-3733.1%
SG&A as share of revenue181.3%
Return on equity-80.6%
Return on assets-68.8%
Return on invested capital-516.1%
Interest coverage-25598.3x
Current ratio7.19
Quick ratio7.19

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.